L-Dopa — NCD 132 | CMS Coverage Update

CMS modified NCD 132 (L-Dopa coverage policy), effective March 7, 2026. Here's what billing teams need to know to avoid claim denials across Part A, SNF, and outpatient physical therapy.

The Centers for Medicare & Medicaid Services updated NCD 132, the National Coverage Determination governing Medicare coverage of L-Dopa (levodopa) therapy for Parkinsonism. This policy spans three benefit categories: inpatient hospital services, diagnostic laboratory tests, and outpatient physical therapy services. No specific CPT or HCPCS codes are listed in the updated policy document, but the coverage criteria governing medical necessity, physical therapy payability, and SNF reimbursement have clear billing implications your team needs to act on now.

---

Quick-Reference Table

Field	Detail Copy
Payer	CMS (Centers for Medicare & Medicaid Services)
Policy	L-Dopa
Policy Code	NCD 132
Change Type	Modified
Effective Date	March 7, 2026
Impact Level	Medium
Specialties Affected	Neurology, Internal Medicine, Skilled Nursing Facilities, Outpatient Physical Therapy
Key Action	Review medical necessity documentation for inpatient L-Dopa admissions and audit physical therapy claims for maintenance vs. restorative distinctions before billing

---

CMS L-Dopa Coverage Criteria and Medical Necessity Requirements 2026

The core of this CMS L-Dopa coverage policy is straightforward, but the details are where billing teams get into trouble. CMS covers inpatient hospital services for L-Dopa administration when those services are medically required — but "medically required" is doing a lot of work in that sentence.

CMS is explicit: a typical, well-functioning, ambulatory Parkinson's patient with no concurrent disease does not need to be hospitalized to start L-Dopa therapy. Hospitalizing that patient and billing Part A is a claim denial waiting to happen. The medical necessity threshold for inpatient admission kicks in when the patient has concurrent disease — specifically cardiovascular, gastrointestinal, or neuropsychiatric conditions that complicate initiation of therapy.

When inpatient admission is medically justified, CMS considers stays under two weeks standard. A four-week stay is not unreasonable, but your documentation needs to support it. If the chart doesn't clearly connect the extended stay to the concurrent condition, expect a denial.

On the drug coverage question: L-Dopa qualifies as a covered inpatient hospital drug because it appears in A.M.A. Drug Evaluations (First Edition, 1971) — the replacement compendia for "New Drugs" under §1861(t) of the Act — and because it would typically have approval from the hospital's pharmacy and drug therapeutics (P&DT) committee. Your billing team doesn't need to verify this for every claim, but if a payer audits inpatient drug costs, this is the authority to cite.

The policy does not require prior authorization by name, but the medical necessity standard is strict enough that robust clinical documentation functions as your practical defense against post-payment review.

---

CMS L-Dopa Laboratory Test Coverage Under NCD 132

The CMS L-Dopa coverage policy covers specific lab tests connected to L-Dopa therapy. These are not optional extras — they're recognized as medically warranted for achieving optimal dosage and managing side effects.

Covered tests include:

• Complete blood count (CBC)
• Liver function tests: SGOT (AST), SGPT (ALT), and/or alkaline phosphatase
• BUN or creatinine
• Urinalysis
• Blood sugar
• Electrocardiogram (ECG)

CMS states these tests are reasonable at weekly intervals in certain cases. Some physicians order them less frequently. Both frequencies are defensible under this policy — the key is that the medical record justifies the frequency chosen.

This applies whether or not the patient is hospitalized. Outpatient L-Dopa billing for lab work falls under the same coverage criteria. If your practice orders these tests in connection with L-Dopa management, document the clinical rationale and you're on solid ground.

---

CMS L-Dopa Physical Therapy Coverage and Non-Covered Maintenance Services

This is the section most likely to generate claim denials if your billing team isn't paying attention.

CMS covers physical therapy following L-Dopa administration under one specific condition: the drug has produced a reduction in rigidity that creates a new or restored functional goal. If L-Dopa reduces the patient's rigidity enough that restorative physical therapy becomes viable, those PT services are payable — but only if they require the skills of a qualified physical therapist and are furnished by or under that therapist's supervision.

Once the patient reaches their restoration potential, the calculus changes. Maintenance services — keeping the patient at their achieved level — do not generally require the skills of a qualified physical therapist under this policy. Billing skilled PT for a maintenance program is the wrong call. CMS is clear that at the maintenance stage, the therapist's role is to evaluate the patient's needs, consult with the physician, and design an appropriate exercise program. The actual carrying out of that maintenance program by non-therapist staff is not payable as physical therapy.

The evaluative services provided by the qualified physical therapist at the maintenance stage are payable. The maintenance program execution is not. If your PT billing team doesn't have a clean workflow to distinguish restorative from maintenance visits in the claim, fix that now — before the March 7, 2026 effective date.

---

CMS L-Dopa Coverage in Skilled Nursing Facilities (SNFs) 2026

NCD 132 explicitly extends L-Dopa coverage to the SNF setting. Initiation of L-Dopa therapy in an SNF is appropriate and covered, using the same medical necessity guidelines that apply to inpatient hospital initiation.

The same patient-type distinctions apply: cover inpatient SNF services for Parkinsonian patients with concurrent cardiovascular, gastrointestinal, or neuropsychiatric conditions. A well-functioning, ambulatory patient without concurrent disease does not meet the medical necessity bar for SNF-level inpatient care at therapy initiation.

For SNF billing teams: the physical therapy rules from Section A apply here too. Restorative PT following L-Dopa-induced rigidity reduction is covered under skilled care. Maintenance programs executed by non-therapist staff are not. The SNF setting doesn't create any special exceptions — the same restorative-vs.-maintenance line applies, and your MDS coordinators and billing staff need to document accordingly.

L-Dopa therapy in the SNF setting also carries the same lab test coverage. Weekly CBC, liver function tests, BUN or creatinine, urinalysis, blood sugar, and ECG are reasonable and covered when clinically indicated.

---

Coverage Indications at a Glance

---

CMS L-Dopa Billing Guidelines and Action Items 2026

Copy Action Items

---

CPT, HCPCS, and ICD-10 Codes for L-Dopa Under NCD 132

NCD 132 does not list specific CPT, HCPCS, or ICD-10 codes. This is not unusual for an NCD of this vintage — the policy predates the modern code-level specificity common in newer coverage determinations.

Your billing team should apply this policy's medical necessity and coverage criteria to the standard codes you already use for:

• Inpatient hospital admission and associated ancillary services
• Diagnostic laboratory tests (CBC, metabolic panels, urinalysis, ECG)
• Outpatient and inpatient physical therapy services
• SNF Part A claims

If you need code-level mapping specific to your payer contracts or MAC jurisdiction, contact your Medicare Administrative Contractor directly. Regional LCDs from your MAC may provide additional code-level guidance that supplements this NCD.

---